End-Stage Renal Disease Market Size to Reach USD 249.0 Billion by 2035, Impelled by Rising Prevalence of Chronic Kidney Disease

March 04, 2025 | Healthcare

VIEW FULL TABLE OF CONTENTS

End-Stage Renal Disease Market Outlook 2025-2035:

The End-Stage Renal Disease market reached a value of USD 84.2 Billion in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 249.0 Billion by 2035, exhibiting a growth rate (CAGR) of 10.39% during 2025-2035. The End-Stage Renal Disease (ESRD) market is undergoing a significant transformation, driven by advancements in diagnostics and therapeutics. Emphasis on early and accurate diagnosis has gained momentum through technologies such as biomarker-based testing, next-generation sequencing (NGS), and artificial intelligence (AI)-powered predictive analytics. Importantly, these have allowed the early detection of chronic kidney disease (CKD) progression, enabling timely interventions and individualized treatment to benefit patient outcomes. Meanwhile, the therapeutic landscape is also undergoing momentous changes with novel drug candidates. Improvements in dialysis technologies-such as home hemodialysis (HHD) and peritoneal dialysis (PD)-benefit patient convenience and quality of life. Kidney transplantation techniques, like xenotransplantation and bioengineered kidneys, extend treatment options for ESRD patients. New-age therapeutics such as SGLT2 inhibitors, anti-fibrotic agents, and novel erythropoiesis-stimulating agents (ESAs) change the management landscape of the disease by preventing complications like anemia, hyperkalemia, and cardiovascular risks. In addition, combination therapies of targeted drugs with the innovations of dialysis or regenerative medicine enhance treatment efficacy and prolong patient survival.

End-Stage Renal Disease Market Outlook

To get more information on this market, Request Sample

Increasing CKD & ESRD Cases

The primary factors driving the end-stage renal disease (ESRD) market are the rising incidence and prevalence of chronic kidney disease (CKD) and the movement toward end-stage renal disease. The increased demand is largely due to a rising incidence of diabetes and hypertension that cause most renal injuries, culminating in ESRD. Additionally, the ever-increasing global demographic shift toward aging will exacerbate the scenario as senescing individuals are at much greater risk for dysfunction in the kidneys because of normal age-related decline and co-morbid conditions. The rise in increased awareness and proactive screening activities has also encouraged early diagnosis of CKDs, allowing for timely interventions that delay disease progression by lifestyle alteration, drug compliance, and a preventive approach to nephrology. Advanced diagnostic technologies such as biomarker-based assays and AI-powered risk assessment tools are increasingly becoming important in spotting individuals at risk. As such, an ever-increasing global burden of CKD promises a growing demand for dialysis and transplantation-orientated therapy as well as innovative therapeutic modalities, hence driving significant growth in market expansion. It also leads to high investment in new theoretical treatment development as well as healthcare infrastructure to combat this growing healthcare challenge.

Expanding Healthcare Infrastructure & Reimbursement Policies

Increased cases of End-Stage Renal Disease (ESRD) are driving governments and private health care to put considerable resources into expanding dialysis centers and specialized clinics for kidney care. This increase in investments translates to the purchase of modern dialysis machines, the advancement of home dialysis programs, and the betterment of transplant facilities, enabling greater patient access to high-quality care. Moreover, favorable reimbursement policies, which include Medicare coverage in the US and expanded insurance programs across the world, have lessened the financial burden of dialysis treatment. Innovative dialysis technologies and advanced therapeutic modalities are now being included in health care coverage by many countries. Telemedicine, along with remote patient monitoring, is changing the way chronic kidney disease (CKD) and ESRD are managed through virtual consultations and real-time health tracking. Therefore, with the further growth of healthcare infrastructure, access, and affordability, the quality of care for ESRD patients will substantially improve.

Regional Analysis:

The End-Stage Renal Disease (ESRD) market is heavily concentrated in developed regions such as the United States, Germany, the UK, France, Italy, Spain, and Japan, where advancements in dialysis technology, kidney transplantation, and nephrology research are driving innovation. The United States plays a pivotal role in this market due to its leadership in biomarker-based diagnostics, AI-driven predictive analytics, and next-generation dialysis machines, alongside a well-established reimbursement framework under Medicare. While current treatment approaches focus on hemodialysis, peritoneal dialysis, and kidney transplantation, significant progress is being made in regenerative medicine, artificial kidneys, and personalized therapies to improve patient outcomes. The market is also being fueled by increased investments in nephrology research, accelerated regulatory approvals for innovative treatment options, and strategic collaborations between pharmaceutical companies, medical device manufacturers, and healthcare providers. These efforts are expanding treatment accessibility, enhancing disease management, and ultimately improving survival rates and quality of life for ESRD patients worldwide.

Key information covered in the report.

Base Year: 2024
Historical Period: 2019-2024
Market Forecast: 2025-2035

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the End-Stage Renal Disease market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the End-Stage Renal Disease market
Reimbursement scenario in the market
In-market and pipeline drugs

Competitive Landscape:

This report offers a comprehensive analysis of current End-Stage Renal Disease-marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. Across the six major continents and 100+ countries, we work alongside our business partners as one team with a common ambition to achieve unparallelled results, gain a competitive edge, and transform industries. IMARC Group excels in understanding its clients’ business priorities and delivering tailored solutions that drive meaningful outcomes. Our client base spans over 3,000 organizations in the private, public, and social sectors, ranging from high-growth startups to Fortune 500 companies.

Contact US

IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Phone Number: - +1 631 791 1145, +91-120-433-0800

Need more help?

Speak to our experienced analysts for insights on the current market scenarios.
Include additional segments and countries to customize the report as per your requirement.
Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
For further assistance, please connect with our analysts.

End-Stage Renal Disease Market Size to Reach USD 249.0 Billion by 2035, Impelled by Rising Prevalence of Chronic Kidney Disease

Purchase Options Discount
Offer

Inquire Before Buying

Benefits of Customization

Personalize this research
Triangulate with your data
Get data as per your format and definition
Gain a deeper dive into a specific application, geography, customer, or competitor
Any level of personalization

Speak to an Analyst

Request Brochure

Get in Touch With Us

UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.

IMARC did an outstanding job in preparing our study. They were punctual and precise, delivering all the data we required in a clear and well-organized format. Their attention to detail and ability to meet deadlines was impressive, making them a reliable partner for our project.

I wanted to express my sincere appreciation for your efforts in handling this matter. Your dedication and commitment have truly been commendable. It is evident that you have put in a tremendous amount of hard work and expertise into resolving the issues at hand. I would also like to take this opportunity to inform you that we are greatly interested

Overall, the deliverable was well organized and my experience with the project team was good. In particular, I appreciated how they responded when I requested additional information and the Japanese version.

The IMARC team were extremely professional and very cooperative. The team were also extremely flexible in making changes and modifications wherever required. The entire experience right from project kick-off to after sales support was fruitful and smooth.

I’d like to express my gratitude for the work you accomplished with the industry report. The way you responded to the requirements and delivered under tight timelines shows your expertise, exceptional work ethic and commitment to your customer’s success. The entire team and company are incredibly thankful for your dedication. Once again, thank you

The market reports from IMARC have been instrumental in guiding our business strategies. We found the reports comprehensive and data-driven, which helped us make informed decisions. The detailed insights and actionable data have consistently provided us with a competitive edge in a rapidly changing alcohol market.

One of the best things about IMARC is their flexibility and predisposition to tailor the reports and adapt to our needs. They are not just great in their researching and consulting solutions, but their service is unparallelled. We’ve worked with them a couple of times and we will keep working with them in future projects.

We recently commissioned multiple market research reports from IMARC, and the insights we received were invaluable. The depth of analysis, accuracy of data, and actionable recommendations have greatly enhanced our strategic decision-making.

The market estimates provided by your team were pretty much in line with what we were theorizing internally. Really appreciate the work on this.

The sale account manager and the service was excellent. The data and market trends gathered from the report was insightful and really assisted while planning future product and growth strategies.

The report is excellent and has good amount of data and our team is extremely happy with the information provided.

Thank you very much for your cooperation and post purchase support. We were really happy with the final deliverable, and the takeaways from the report.